FDA is reminded
to submit collections as "extensions" when they do not include
changes. Also, prior terms remain in effect: This approval does not
extend to those provisions proposed in the August 29, 2006 NPRM (71
Fed. Reg. 51276). When that rule is finalized, FDA must submit
those changes for approval before they go into effect.
Inventory as of this Action
Requested
Previously Approved
08/31/2017
36 Months From Approved
08/31/2015
45,168
0
45,168
227,222
0
227,222
0
0
0
Sections 701 and 702 of FDASIA direct
the Secretary to specify a UFI system for registration of domestic
and foreign drug establishments, and that each initial and annual
drug establishment registration include a UFI. The "Guidance for
Industry on Specification of the Unique Facility Identifier (UFI)
System for Drug Establishment Registration" specifies that FDA's
preferred UFI for a drug establishment is the DUNS number. The DUNS
number is available free of charge to all drug establishments. As
explained in the guidance, however, if a company wants to use an
alternative UFI for its drug establishment, it may contact
FDA.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.